{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:45:56Z","timestamp":1789994756197,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.jconrel.2008.09.091","type":"journal-article","created":{"date-parts":[[2008,10,22]],"date-time":"2008-10-22T05:19:39Z","timestamp":1224652779000},"page":"172-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db\/db mice"],"prefix":"10.1016","volume":"133","author":[{"given":"Cheng-Hao","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Young","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohee","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Key An","family":"Um","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Seok","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seulki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Choon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2008.09.091_bib1","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2008.09.091_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1900\/RDS.2005.2.61","article-title":"New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins","volume":"2","author":"Gallwitz","year":"2005","journal-title":"Rev. Diabet. Stud."},{"key":"10.1016\/j.jconrel.2008.09.091_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1464-5491.2006.02071.x","article-title":"Incretins and other peptides in the treatment of diabetes","volume":"24","author":"Todd","year":"2007","journal-title":"Diabet. Med."},{"key":"10.1016\/j.jconrel.2008.09.091_bib4","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2008.09.091_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/meta.2001.22519","article-title":"Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro","volume":"50","author":"Parkes","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.jconrel.2008.09.091_bib6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diabetes.48.5.1026","article-title":"Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)","volume":"48","author":"Young","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2008.09.091_bib7","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jcem.87.3.8337","article-title":"The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes","volume":"87","author":"Egan","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2008.09.091_bib8","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2008.09.091_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.jconrel.2008.09.091_bib10","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1210\/endo.141.6.7490","article-title":"Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats","volume":"141","author":"Szayna","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2008.09.091_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1081\/PDT-65686","article-title":"Oral delivery of mono-PEGylated sCT (Lys18) in rats: regional difference in stability and hypocalcemic effect","volume":"10","author":"Mansoor","year":"2005","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2008.09.091_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ejpb.2007.07.009","article-title":"Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation","volume":"68","author":"Youn","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2008.09.091_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/bc700292v","article-title":"Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery","volume":"19","author":"Chae","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2008.09.091_bib14","doi-asserted-by":"crossref","first-page":"G73","DOI":"10.1152\/ajpgi.00059.2003","article-title":"Biotin uptake by human intestinal and liver epithelial cells: role of the SMVT system","volume":"285","author":"Balamurugan","year":"2003","journal-title":"Am. J. Physiol., Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jconrel.2008.09.091_bib15","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1023\/A:1010932126662","article-title":"Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide","volume":"18","author":"Ramanathan","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2008.09.091_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/bc049735+","article-title":"Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1","volume":"16","author":"Lee","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2008.09.091_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bcp.2006.09.013","article-title":"Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability, and proteolytic stability","volume":"73","author":"Youn","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2008.09.091_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.regpep.2006.12.021","article-title":"Biological activity of AC3174, a peptide analog of exendin-4","volume":"141","author":"Hargrove","year":"2007","journal-title":"Regul. Pept."},{"key":"10.1016\/j.jconrel.2008.09.091_bib19","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00125-006-0234-3","article-title":"PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db\/db mice","volume":"49","author":"Lee","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2008.09.091_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs: barriers and developments","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2008.09.091_bib21","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1023\/A:1016008419367","article-title":"Oral controlled release technology for peptides: status and future prospects","volume":"13","author":"Fix","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2008.09.091_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1248\/yakushi1947.117.7_394","article-title":"Delivery system design for improvement of intestinal absorption of peptide drugs","volume":"117","author":"Muranishi","year":"1997","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.jconrel.2008.09.091_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.30","article-title":"Emerging trends in oral delivery of peptide and protein drugs","volume":"20","author":"Mahato","year":"2003","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2008.09.091_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(97)00204-6","article-title":"The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins","volume":"52","author":"Bernkop-Schn\u00fcrch","year":"1998","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365908006275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365908006275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:22:10Z","timestamp":1759159330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365908006275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0168365908006275"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2008.09.091","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db\/db mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2008.09.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}